医学
化学预防
肺结核
潜伏性肺结核
内科学
乙型肝炎病毒
乙型肝炎
拉米夫定
结核菌素
免疫学
结核分枝杆菌
病毒
病理
作者
Rongbei Liu,Zhilun Li,Lingna Ye,Jing Hu,Jian Tang,Baili Chen,Xiuli Chen,Bei Tan,Yubei Gu,Chen Xie,Chunhui Ouyang,Xiaomei Song,Fan Li,Yanyun Fan,Haixia Ren,Liangru Zhu,Min Chen,Wenyu Jiang,Qian Cao
出处
期刊:Inflammatory Bowel Diseases
[Oxford University Press]
日期:2023-03-06
卷期号:30 (1): 45-52
被引量:2
摘要
Abstract Background Ustekinumab (UST) was approved in China for moderate-to-severe Crohn’s disease (CD) in 2020. The prevalence rates of tuberculosis and hepatitis B virus (HBV) infection are high in China, and no guideline clearly states that tuberculosis chemoprophylaxis or prophylactic anti-HBV therapy should be prescribed before UST administration. This study aimed to assess the risk of tuberculosis and HBV reactivation in CD patients with latent tuberculosis infection (LTBI) and previous HBV infection receiving UST. Methods A multicenter retrospective cohort study was carried out at 68 hospitals in China to assess 721 adult CD cases administered UST between May 1, 2020, and December 31, 2021. CD and concurrent LTBI or HBV carrier were included. Hepatitis B serology, T-SPOT.TB, and tuberculin skin tests were performed at baseline. The primary outcome was tuberculosis or HBV reactivation. Results Patients with CD-concomitant LTBI or who were HBV carriers receiving UST therapy were retrospectively enrolled from 15 hospitals in China. A total of 53 CD with LTBI patients and 17 CD with HBV carrier patients receiving UST were included. Treatment and follow-up durations were 50 ± 20 weeks and 50 ± 15 weeks in the LTBI and HBV carrier groups, respectively. A total of 25 CD patients with LTBI underwent chemoprophylaxis and 28 did not. A total of 11 HBV carriers had antiviral prophylaxis and 6 did not. No patient experienced tuberculosis or HBV reactivation or liver dysfunction during follow-up. Conclusions UST was safe for treatment of CD because no patient developed tuberculosis, persistent hepatitis, or acute liver failure during therapy, whether with a prophylactic regimen or not, based on our sample size and limited follow-up time.
科研通智能强力驱动
Strongly Powered by AbleSci AI